Literature DB >> 32649012

Th17/Treg imbalance modulates rat myocardial fibrosis and heart failure by regulating LOX expression.

Min Lu1, Xinglei Qin2, Jungong Yao1, Yuanyuan Yang1, Minghu Zhao1, Lin Sun1.   

Abstract

AIM: The imbalance of T helper (Th) 17/T regulatory (Treg) is involved in chronic heart failure (HF). The enzyme lysyl oxidase (LOX) contributes to myocardial fibrosis. This study was designed to decipher the regulatory mechanism of Th17/Treg on LOX expression and to validate whether Th17/Treg imbalance regulates myocardial fibrosis by modulating LOX expression.
METHODS: Human cardiac fibroblasts (HCFs) were treated with angiotensin II (Ang II) and co-cultured with Th17 cells and Tregs which were polarized from control naïve CD4+ T cells. Th17 cells and Tregs were adoptively transferred into abdominal aortic coarctation-induced chronic HF rats to investigate the efficacy of Th17 and Treg infusions on myocardial fibrosis and HF.
RESULTS: Th17/Treg imbalance (increased Th17 cells and decreased Tregs) was observed in HF patients. Th17 cells/Tregs aggravated/attenuated Ang II-induced upregulation of LOX and fibrosis-related indicators (MMP-2/9 and collagen I/III) in HCFs in vitro and abdominal aortic coarctation-induced myocardial fibrosis and HF in rats, by promoting/inhibiting LOX expression. Mechanistically, Th17 cells promoted LOX expression by activating the IL-17/ERK1/2-AP-1 pathway, while Tregs inhibited LOX expression by activating the IL-10/JAK1-STAT3 pathway.
CONCLUSION: Increased Th17 cells and decreased Tregs aggravate myocardial fibrosis and HF by inducing LOX expression.
© 2020 Scandinavian Physiological Society. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  LOX; Th17; Treg; cardiac fibrosis; heart failure

Year:  2020        PMID: 32649012     DOI: 10.1111/apha.13537

Source DB:  PubMed          Journal:  Acta Physiol (Oxf)        ISSN: 1748-1708            Impact factor:   6.311


  8 in total

Review 1.  Cardiac Remodelling Following Cancer Therapy: A Review.

Authors:  Tan Panpan; Du Yuchen; Shi Xianyong; Liu Meng; He Ruijuan; Dong Ranran; Zhang Pengyan; Li Mingxi; Xie Rongrong
Journal:  Cardiovasc Toxicol       Date:  2022-07-25       Impact factor: 2.755

2.  Full-Length Transcriptome Sequencing: An Insight Into the Dog Model of Heart Failure.

Authors:  Xiaoyan Liang; Zechen Bai; Feifei Wang; Yafan Han; Huaxin Sun; Jiasuoer Xiaokereti; Ling Zhang; Xianhui Zhou; Yanmei Lu; Baopeng Tang
Journal:  Front Cardiovasc Med       Date:  2021-12-16

3.  VCAM1 expression in the myocardium is associated with the risk of heart failure and immune cell infiltration in myocardium.

Authors:  Tongyu Wang; Jiahu Tian; Yuanzhe Jin
Journal:  Sci Rep       Date:  2021-09-30       Impact factor: 4.379

4.  β-Hydroxybutyrate Mitigated Heart Failure with Preserved Ejection Fraction by Increasing Treg Cells via Nox2/GSK-3β.

Authors:  Shengen Liao; Yuan Tang; Xin Yue; Rongrong Gao; Wenming Yao; Yanli Zhou; Haifeng Zhang
Journal:  J Inflamm Res       Date:  2021-09-16

Review 5.  Intestinal Fibrosis in Inflammatory Bowel Disease and the Prospects of Mesenchymal Stem Cell Therapy.

Authors:  Yifei Wang; Bin Huang; Tao Jin; Dickson Kofi Wiredu Ocansey; Jiajia Jiang; Fei Mao
Journal:  Front Immunol       Date:  2022-03-18       Impact factor: 7.561

Review 6.  Immune remodeling and atrial fibrillation.

Authors:  Yajun Yao; Mei Yang; Dishiwen Liu; Qingyan Zhao
Journal:  Front Physiol       Date:  2022-07-22       Impact factor: 4.755

Review 7.  The underlying pathological mechanism of ferroptosis in the development of cardiovascular disease.

Authors:  Li-Li Zhang; Rui-Jie Tang; Yue-Jin Yang
Journal:  Front Cardiovasc Med       Date:  2022-08-08

8.  Infusion of two-dose mesenchymal stem cells is more effective than a single dose in a dilated cardiomyopathy rat model by upregulating indoleamine 2,3-dioxygenase expression.

Authors:  Chenyi Gong; Lei Chang; Xuan Sun; Yu Qi; Rong Huang; Ke Chen; Bin Wang; Lina Kang; Lian Wang; Biao Xu
Journal:  Stem Cell Res Ther       Date:  2022-08-12       Impact factor: 8.079

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.